Peptide education
Ganirelix
Ganirelix acetate
Ganirelix is a prescription medicine used during ovarian stimulation to help prevent an early luteinizing hormone (LH) surge. The referenced U.S. ganirelix acetate injection is given under the skin as part of fertility treatment, with the ovarian response monitored by a clinician.
An established fertility medicine for preventing a premature LH surge, used within a monitored ovarian stimulation cycle.
Overview
Quick answer
Ganirelix holds back a hormone signal that could trigger ovulation too soon. It is not the follicle-stimulating medicine used in the same cycle and it does not guarantee pregnancy. Cetrorelix is another GnRH antagonist, but it is a different medicine with its own label.
Why is ganirelix used in fertility treatment?
It helps prevent an early LH surge while follicles develop. That gives the care team more control over the timing of final egg maturation and retrieval.
What does the U.S. label say about dosing?
The referenced label describes 250 micrograms, or 0.25 mg, under the skin once daily during the middle to later follicular phase, continuing until the day hCG is given. The fertility team determines the treatment plan. This is label context, not an individual prescription.
Is ganirelix the same drug as cetrorelix?
No. Both block GnRH receptors, but they are different drugs. A study compared particular regimens and does not establish that a patient can switch without clinical direction.
What safety issues matter?
Serious allergic reactions have been reported, including after a first dose. Ovarian hyperstimulation syndrome can occur during the wider stimulation cycle. Known or suspected pregnancy and certain allergies are contraindications, and the label says not to use ganirelix while lactating.
Evidence
Evidence snapshot
The U.S. label identifies inhibition of premature LH surges during controlled ovarian hyperstimulation and summarizes controlled studies.
Among 463 patients given 250 micrograms, the label reports a premature surge in less than 1% using its combined hormone criteria before hCG. A hormone rise alone is not the same endpoint.
A successful block of an LH surge does not remove the risk of ovarian hyperstimulation or allergic reactions during treatment.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Ganirelix helps prevent ovulation from happening too early during stimulation. | Controlled studies summarized in the label measured premature LH surges during ovarian stimulation. The label defines the surge using LH and other hormone changes. | Ganirelix blocks pituitary GnRH receptors, suppressing gonadotropin release and helping prevent a premature LH surge. | Supported for the labeled, monitored setting. A suppressed LH surge is not a guarantee of retrieval, pregnancy, or live birth. |
| A trial proves ganirelix and a long leuprolide protocol produce identical results. | In one randomized trial, ongoing pregnancy per attempt was 30.8% with ganirelix and 36.4% with leuprolide. Mean retrieved oocytes per attempt were 11.6 and 14.1, respectively. | The study reported outcomes in both groups, but those results do not prove identical outcomes or predict an individual patient's chance of live birth. | |
| Ganirelix removes the risk of ovarian hyperstimulation syndrome. | The ganirelix label reports ovarian hyperstimulation syndrome among events seen during treatment. Monitoring and decisions about the rest of the stimulation cycle still matter. | Not supported. A GnRH antagonist does not make a stimulation cycle risk-free. |
Bottom line
Main takeaway
Ganirelix helps the fertility team manage timing. It does not mature eggs on its own.
Check the exact medicine and instructions with the fertility team, including the start time, monitoring plan, allergy history, and what to do if symptoms develop.
Keep the label's hormone-defined surge endpoint separate from pregnancy outcomes in the leuprolide comparison and from the different regimens in the cetrorelix comparison.
Identity
What it is
Ganirelix is a synthetic peptide with ten amino acids. The referenced ganirelix acetate product is a single-dose prefilled syringe for injection beneath the skin.
In controlled ovarian stimulation, follicle-stimulating hormone is used to support follicle development. Ganirelix has a different job: it suppresses the signal that can cause premature ovulation.
Use context
Routes, doses, and cycle patterns
The following regimens describe a U.S. product label and a published study. They are not recommendations for starting, changing, or replacing an individual fertility plan.
Human studies and product labels
Ganirelix acetate injection U.S. label
- Purpose
- Inhibit premature LH surges during controlled ovarian hyperstimulation
- Context
- Prescription product label
- Route
- Subcutaneous
- Amount
- 250 micrograms, equivalent to 0.25 mg
- Frequency
- Once daily during the middle to later follicular phase
- Duration
- Continued daily until the day hCG is administered
The label places treatment within clinician-directed ovarian stimulation and ultrasound assessment. This is not a personalized schedule.
Ganirelix versus cetrorelix trial
- Purpose
- Prevent a premature LH surge before assisted reproduction
- Context
- Open-label randomized comparison in programmed stimulation cycles
- Route
- Subcutaneous
- Amount
- 0.25 mg ganirelix
- Frequency
- Once daily after the study's follicle-size criterion was met
- Duration
- Depended on the timing of hCG
The comparison group received an initial 3 mg cetrorelix dose and additional daily cetrorelix when needed. This is study-reported use, not a switching plan.
What varies
- Treatment timing: the clinician coordinates the antagonist, stimulation medicines, monitoring, and any trigger.
- Product: the referenced label describes a 250 microgram per 0.5 mL single-dose prefilled syringe.
- Medical history: pregnancy, lactation, and specified allergies affect use of ganirelix.
Research
Research evidence
The label summarizes controlled studies of daily ganirelix during ovarian stimulation. A separate randomized trial compared a ganirelix protocol with long leuprolide treatment. Those findings describe specific populations and protocols, not a guarantee of pregnancy or a general fertility benefit.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Ganirelix label study summary | Women undergoing controlled ovarian hyperstimulation for assisted reproduction | Ganirelix arm of a multicenter, open-label randomized study summarized in the label | 250 micrograms ganirelix daily | A premature LH surge before hCG, defined by combined hormone criteria, occurred in less than 1% of 463 patients in the label summary. | The studies intended to exclude some populations. Surge prevention is not the same outcome as live birth. | Substantial human evidence |
| Ganirelix versus leuprolide | 313 patients undergoing stimulation for IVF or intracytoplasmic sperm injection | Multicenter, open-label phase 3 randomized trial | Ganirelix protocol versus long leuprolide protocol | Ongoing pregnancy per attempt was 30.8% with ganirelix and 36.4% with leuprolide; mean retrieved oocytes per attempt were 11.6 and 14.1, respectively. | A single trial cannot establish identical outcomes or predict live birth for an individual. | Controlled human study |
| Ganirelix versus cetrorelix | 185 patients undergoing programmed ovarian stimulation for assisted reproduction | Open-label randomized comparison | Daily 0.25 mg ganirelix versus initial 3 mg cetrorelix | The study reported no premature LH surge in either group by its day-of-trigger definition. | It did not compare the two current daily U.S. product regimens and cannot establish patient-level interchangeability. | Controlled human study |
Cautions
Safety and unknowns
- Abdominal pain, headache, injection-site reactions, and nausea were among events reported in the label's clinical studies. These reports do not establish that every event was caused by ganirelix.
- Serious hypersensitivity, including anaphylaxis, has been reported as early as the first dose. Tell the fertility team about known allergies or prior reactions.
- The label contraindicates ganirelix with known or suspected pregnancy or specified hypersensitivity to the drug, its components, GnRH, or related analogs. It says not to use ganirelix during lactation.
- Ovarian hyperstimulation syndrome can occur during fertility treatment. Contact the fertility clinic promptly for abdominal pain or bloating, vomiting, or faintness. Difficulty breathing or chest pain needs emergency care.
Product quality
Product identity and quality
The referenced product is a labeled, single-dose prefilled syringe. Its evidence does not verify another product's contents, sterility, or storage history.
Product and strength
The referenced syringe contains 250 micrograms in 0.5 mL. A different product should not be assumed to have the same preparation or instructions.
Handling and storage
The referenced label specifies controlled room-temperature storage and protection from light. Follow the product's own instructions and the fertility team's guidance.
Mechanism
How it is proposed to work
Ganirelix blocks a pituitary receptor for GnRH. This reduces LH release and helps prevent the early surge that could trigger ovulation.
GnRH ordinarily signals the pituitary to release LH and FSH. Ganirelix competes for the receptor and suppresses gonadotropin release.
The label describes a reversible effect after treatment is stopped. The antagonist does not replace the separate medicines used for follicle stimulation or final maturation.
FAQ
Common questions
What is ganirelix used for?
Ganirelix acetate injection is labeled to inhibit premature LH surges during controlled ovarian hyperstimulation. It is part of a monitored fertility treatment, not a drug that grows follicles by itself.
Is ganirelix the same as cetrorelix?
Both are GnRH antagonists, but they are different drugs. A trial compared specific regimens; it does not establish that a patient can switch products without a clinician's direction.
Does ganirelix eliminate ovarian hyperstimulation syndrome?
No. Ovarian hyperstimulation syndrome can occur during a stimulation cycle. Symptoms and ovarian response need assessment by the fertility team.
Details
Technical details
Sources
References
- 1.
DailyMed. Ganirelix acetate injection prescribing information
U.S. product label for indication, administration, trial results, contraindications, and safety.
- 2.
PubMed. Efficacy and safety of ganirelix acetate versus leuprolide acetate in ovarian stimulation
doi:10.1016/s0015-0282(00)01638-1 PMID:11163814
Phase 3 open-label randomized trial comparing ganirelix and a long leuprolide protocol.
- 3.
PubMed. Randomized trial comparing cetrorelix and ganirelix in assisted reproduction
doi:10.1016/j.fertnstert.2005.03.016 PMID:16009165
Open-label trial comparing a 3 mg cetrorelix regimen with daily 0.25 mg ganirelix.
- 4.
NHS. IVF: possible complications
Patient-facing information on symptoms and urgent care during fertility treatment.